<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg"/></p>
<p>Sensei Biotherapeutics 正在準備結束其主要資產的臨牀研究，同時考慮出售公司。圖片來源：eamesBot/ Shutterstock.com。</p>
<p>Sensei Biotherapeutics 將放棄其唯一的臨牀階段資產 solnerstotug，並準備裁減員工，考慮下一步行動。</p>
<p>這一消息在這家免疫腫瘤生物技術公司發佈了針對實體腫瘤候選藥物的積極 I 期劑量擴展數據並宣佈計劃進入 II 期測試後僅幾周傳出。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>免疫腫瘤學 (IO) - 主題情報</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>在一項 I/II 期研究 (NCT05864144) 中，接受 15mg/kg solnerstotug 治療的抗 PD-L1 耐藥患者的六個月無進展生存期 (PFS) 達到 50%。Solnerstotug 是一種單克隆抗體，針對 T 細胞激活的 V 域 Ig 抑制因子 (VISTA)，設計為在低 pH 腫瘤微環境中有條件活躍。該數據在 2025 年 10 月 17-21 日於德國柏林舉行的歐洲醫學腫瘤學會 (ESMO) 大會上發佈。</p>
<p>根據其在 ESMO 會議後的公告，Sensei 原計劃在 2026 年啓動兩項 II 期研究，針對抗 PD-L1 耐藥的非小細胞肺癌 (NSCLC) 和梅克爾細胞癌 (MCC)，這取決於 FDA 的反饋和資本籌集。</p>
<p>現在看來，這家生物技術公司已撤回進一步臨牀測試的計劃，並正在探索未來的選項，包括出售其資產、合併、出售公司或結束運營。根據 Sensei 的説法，這一決定來自董事會，經過對公司管道和市場狀況的廣泛討論。該生物技術公司還表示，計劃裁員以保留現金。</p>
<p>“我們現在的角色是謹慎管理公司及其資產，包括有序結束正在進行的 I/II 期臨牀試驗和保護股東價值，” Sensei 的總裁兼首席執行官 John Celebi 説道。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報的信息</p>
<h2>Sensei 的動盪歷史</h2>
<p>去年，Sensei 宣佈將裁減 46% 的員工，並關閉位於美國馬里蘭州羅克維爾的研究中心。這一舉措被描述為一次全公司範圍的重組，旨在將資源集中於推進 solnerstotug，當時稱為 SNS-101，在公司 2024 年第三季度財報發佈中提到。</p>
<p>近年來，Sensei 遭遇了多次挫折，包括一系列被放棄的臨牀和前臨牀項目。早在 2021 年，這家生物技術公司就停止了 SNS-301 的開發，這是其唯一一個進入臨牀階段的資產。SNS-301 是一種首創的納米顆粒疫苗，針對人類天冬氨酸 β-羥化酶 (ASPH)，並在包括慢性髓系單核細胞白血病 (CMML) 和頭頸部鱗狀細胞癌 (HNSCC) 在內的多種癌症類型中進行研究。在過去幾年中，至少有四項針對 SNS-301 的 I 期或 II 期試驗在宣佈後被撤回或終止，依據是 GlobalData，<em>Pharmaceutical Technology</em> 的母公司。</p>
<h2>製藥技術卓越獎 - 參賽的好處</h2>
<p>獲得應有的認可！製藥技術卓越獎 慶祝創新、領導力和影響力。通過參賽，您展示了自己的成就，提升了行業形象，並將自己定位於推動製藥進步的頂尖領導者之中。不要錯過脱穎而出的機會 - 今天就提交您的參賽作品！</p>
<p>立即提名</p>

SNSE

<p>Sensei Biotherapeutics 正在停止其主要臨牀階段資產 solnerstotug 的開發，並裁減員工，作為旨在最大化股東價值的戰略審查的一部分。儘管第一階段數據表現積極，公司仍在探索包括出售或合併在內的選項。此決定是在之前裁員和臨牀管道遭遇挫折之後做出的。首席執行官 John Celebi 強調在這一過渡期間需要保護現金和股東價值</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg"/></p>
<p>Sensei Biotherapeutics is preparing to wind-down clinical investigation of its lead asset, as it considers a company sale. Credit: eamesBot/ Shutterstock.com.</p>
<div class="lb-trans"><p>Sensei Biotherapeutics 正在準備結束其主要資產的臨牀研究，同時考慮出售公司。圖片來源：eamesBot/ Shutterstock.com。</p>
</div><p>Sensei Biotherapeutics is set to abandon its sole clinical-stage asset solnerstotug as it prepares to cut its workforce and consider next steps.</p>
<div class="lb-trans"><p>Sensei Biotherapeutics 將放棄其唯一的臨牀階段資產 solnerstotug，並準備裁減員工，考慮下一步行動。</p>
</div><p>This news comes just weeks after the immuno-oncology biotech released positive Phase I dose expansion data for the solid-tumour candidate and announced plans to proceed to Phase II testing.</p>
<div class="lb-trans"><p>這一消息在這家免疫腫瘤生物技術公司發佈了針對實體腫瘤候選藥物的積極 I 期劑量擴展數據並宣佈計劃進入 II 期測試後僅幾周傳出。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>Immuno-oncology (IO) - Thematic Intelligence</h4>
<div class="lb-trans"><h4>免疫腫瘤學 (IO) - 主題情報</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>In a Phase I/II study (NCT05864144) with the drug, the six-month progression-free survival (PFS) reached 50% in anti-PD-L1 resistant patients treated with 15mg/kg solnerstotug. Solnerstotug is a monoclonal antibody targeting V-domain Ig suppressor of T-cell activation (VISTA), designed to be conditionally active in a low-pH tumour microenvironment. This data was presented at the European Society for Medical Oncology (ESMO) Congress 2025, held October 17–21 in Berlin, Germany.</p>
<div class="lb-trans"><p>在一項 I/II 期研究 (NCT05864144) 中，接受 15mg/kg solnerstotug 治療的抗 PD-L1 耐藥患者的六個月無進展生存期 (PFS) 達到 50%。Solnerstotug 是一種單克隆抗體，針對 T 細胞激活的 V 域 Ig 抑制因子 (VISTA)，設計為在低 pH 腫瘤微環境中有條件活躍。該數據在 2025 年 10 月 17-21 日於德國柏林舉行的歐洲醫學腫瘤學會 (ESMO) 大會上發佈。</p>
</div><p>Sensei had planned to initiate two Phase II studies in 2026 in patients with anti-PD-L1-resistant non-small cell lung cancer (NSCLC) and merkel cell carcinoma (MCC) subject to FDA feedback and capital fundraising, as per its announcement following the ESMO presentations.</p>
<div class="lb-trans"><p>根據其在 ESMO 會議後的公告，Sensei 原計劃在 2026 年啓動兩項 II 期研究，針對抗 PD-L1 耐藥的非小細胞肺癌 (NSCLC) 和梅克爾細胞癌 (MCC)，這取決於 FDA 的反饋和資本籌集。</p>
</div><p>It now emerges that the biotech has withdrawn plans for further clinical testing and is exploring options for the future, including a sale of its assets, a merger, a sale of the company, or a wind-down of operations. The decision comes from the Board of Directors after extensive discussions around the company’s pipeline and market conditions, according to Sensei. The biotech also said it plans to initiate job losses in an effort to preserve cash.</p>
<div class="lb-trans"><p>現在看來，這家生物技術公司已撤回進一步臨牀測試的計劃，並正在探索未來的選項，包括出售其資產、合併、出售公司或結束運營。根據 Sensei 的説法，這一決定來自董事會，經過對公司管道和市場狀況的廣泛討論。該生物技術公司還表示，計劃裁員以保留現金。</p>
</div><p>“Our role now is to steward the company and its assets with care, including an orderly wind-down of the ongoing Phase I/II clinical trial and preservation of shareholder value,” said John Celebi, president and CEO of Sensei.</p>
<div class="lb-trans"><p>“我們現在的角色是謹慎管理公司及其資產，包括有序結束正在進行的 I/II 期臨牀試驗和保護股東價值，” Sensei 的總裁兼首席執行官 John Celebi 説道。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報的信息</p>
</div><h2>Sensei’s turbulent history</h2>
<div class="lb-trans"><h2>Sensei 的動盪歷史</h2>
</div><p>Last year, Sensei had announced it would be slashing 46% percent of its workforce and closing its research site in Rockville, Maryland, US. The move was described as an organisation-wide restructure to focus its resources on advancing solnerstotug, then called SNS-101, in the company’s Q3 earnings press release in November 2024.</p>
<div class="lb-trans"><p>去年，Sensei 宣佈將裁減 46% 的員工，並關閉位於美國馬里蘭州羅克維爾的研究中心。這一舉措被描述為一次全公司範圍的重組，旨在將資源集中於推進 solnerstotug，當時稱為 SNS-101，在公司 2024 年第三季度財報發佈中提到。</p>
</div><p>Sensei has suffered multiple setbacks in recent years, including a series of abandoned clinical and preclinical programmes. Back in 2021, the biotech discontinued development of SNS-301, its only other asset to reach clinical-stage investigation. SNS-301 was a first-in-class nanoparticle vaccine targeting human aspartate β-hydroxylase (ASPH) and was being investigated in various cancer types including chronic myelomonocytic leukemia (CMML) and head and neck squamous cell carcinoma (HNSCC). In the last few years, at least four Phase I or II-stage trials investigating SNS-301 were withdrawn or terminated after being announced, as per GlobalData, the parent company of <em>Pharmaceutical Technology</em>.</p>
<div class="lb-trans"><p>近年來，Sensei 遭遇了多次挫折，包括一系列被放棄的臨牀和前臨牀項目。早在 2021 年，這家生物技術公司就停止了 SNS-301 的開發，這是其唯一一個進入臨牀階段的資產。SNS-301 是一種首創的納米顆粒疫苗，針對人類天冬氨酸 β-羥化酶 (ASPH)，並在包括慢性髓系單核細胞白血病 (CMML) 和頭頸部鱗狀細胞癌 (HNSCC) 在內的多種癌症類型中進行研究。在過去幾年中，至少有四項針對 SNS-301 的 I 期或 II 期試驗在宣佈後被撤回或終止，依據是 GlobalData，<em>Pharmaceutical Technology</em> 的母公司。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 參賽的好處</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>獲得應有的認可！製藥技術卓越獎 慶祝創新、領導力和影響力。通過參賽，您展示了自己的成就，提升了行業形象，並將自己定位於推動製藥進步的頂尖領導者之中。不要錯過脱穎而出的機會 - 今天就提交您的參賽作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

Sensei Biotherapeutics 將在戰略評估中放棄其主要候選藥物並裁減員工